Antiarrhythmic Agents

- Antiarrhythmics are divided into four main classes based on their predominant electrophysiological action:
  - Class I – Sodium channel blockers
  - Class II – Beta blockers
  - Class III – Potassium channel blockers
  - Class IV – Calcium channel blockers

Class I – Sodium Channel Blockers
- Depress the fast inward sodium currents in myocardial cells to suppress their automaticity and increase resting potential.
- This class is further divided into 3 levels:
  - Class IA
    - Actions are related to QT prolongation and may worsen cardiac failure.
    - Metabolized by the liver and can be monitored with serum concentrations.
    - Have activity against atrial and ventricular arrhythmias.
    - Drugs in this class include:
      » Disopyramide (Norpace)
      » Procainamide (Procan, Pronestyl)
      » Quinidine
- Class IB
  - Commonly used and are less likely to have proarrhythmic effects.
  - CNS toxicity is common.
  - Limited to treatment of ventricular arrhythmias.
  - Drugs in this class include:
    » Lidocaine
    » Mexiletine (Mexitil)
    » Tocainide (Tonecard)
- Class IC
  - Not commonly used and some were removed from the market because of their proarrhythmic side effects.
  - Indicated for supraventricular arrhythmias, but also have activity against ventricular arrhythmias.
  - Drugs in this class include:
    » Flecainide (Tambocor)
    » Propafenone (Rythmol)

Class II – Beta Blockers
- Inhibit cardiac and pulmonary β receptors, causing bradycardia, decreased contractility, and the potential for bronchoconstriction.
- Used to treat hypertension, reduce infarct size in the peri-infarction period, and used as adjuncts for rate control in atrial fibrillation or flutter and to convert or prevent SVT.
- Actions of beta blocking agents include:
  - Decreased myocardial contractility.
  - Prolonged AV conduction time.
  - Suppressed myocardial automaticity, resulting in decreased heart rate, cardiac output, and systemic arterial pressure. All effects are due to beta-adrenergic blockade on the cardiac beta receptors.
Antiarrhythmic Agents

• Class II – Beta Blockers
  – Drugs in this class include
    • Acebutolol (Sectral)
    • Atenolol (Tenormin)
    • Esmolol (Brevibloc)
    • Metoprolol (Lopressor)
    • Nadolol (Vaken)
    • Propranolol (Inderal)

• Class III – Potassium Channel Blockers
  – Class III agents are effective for both supraventricular and ventricular arrhythmias
  – Drugs in this class include:
    • Amiodarone (Cordarone, Pacerone)
    • Dofetilide (Tikosyn)
    • Ibutilide (Corvert)

• Class IV – Calcium Channel Blockers
  – Three major types are available
    - dihydropyridines, which do not slow the heart rate or cause other abnormal heart rates or rhythms (cardiac arrhythmias)
    - Examples include
      - amlodipine (Norvasc)
      - sustained release nifedipine (Procardia XL, Adalat CC)
      - felodipine (Plendil)
      - nisoldipine (Sular)
      - clevidipine (Cleviprex)
      - nicardipine (Cardene)

  – The other two types of calcium channel blockers are referred to as the non-dihydropyridine agents
    • verapamil (Calan, Covera, Isoptin, Verelan)
    • diltiazem (Cardizem, Tiazac, Dilacor, and Dilta).

Other Antiarrhythmics

• Adenosine (Adenocard)
  – an endogenous nucleoside occurring in all cells of the body
  – slows conduction time through the A-V node
  – can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT)

• Digoxin (Lanoxin)
  – increases the strength and vigor of heart contractions
  – used to treatment of heart failure
  – increases the force of contraction of the muscle of the heart by inhibiting the activity of ATPase which increases calcium in heart muscle and therefore increases the force of heart contractions

Antiarrhythmic Agents

Antianginal Agents
Antianginal Agents

- **Actions**
  - Relax and dilate vascular smooth muscle of both arterial and venous vessels
  - Improves coronary circulating blood flow
  - Decreases myocardial O2 consumption
  - Decreases systemic and peripheral vascular resistance and arterial pressure
  - Decreases elevated CVP, PCWP and pulmonary vascular resistance

- **Indications**
  - IV: control and prevention of hypertensive episodes due to surgery, cardiovascular procedures and CAB; CHF associated with acute MI
  - Sublingual: relief of acute angina; to decrease myocardial work in pts with acute MI or CHF

- **Drugs in this class include**
  - Nitroglycerin (Tridel, Nitrostat, Nitrobid)

Antihypertensive Agents

- **Arterial blood pressure**
  - Determined by blood flow and the resistance to blood flow
  - Highest during cardiac systole; lowest at the end of diastole
  - Hypertension (HTN) can damage the heart, brain, kidney and eye
  - Referred to as cardiovascular disease (CVD)
    - uncontrolled HTN increases CVD morbidity and mortality due to increased risk of left ventricular hypertrophy, angina, MI, cardiac failure, stroke, PAH, retinopathy, and renal failure
  - Blood pressure values are categorized according to the following table

Vasopressors and Inotropes

- **Indications**
  - Sympathomimetic agents used in shock to treat hypoperfusion and provide hemodynamic support

- **Action**
  - Increase myocardial contractility, constrict capacitance vessels and dilate resistance vessels

- **Drugs in this group include**
  - norepinephrine (Levophed)
  - epinephrine (Adrenaline)
  - dopamine (Intropin)
  - isoproterenol (Isuprel)
  - Phenylephrine (Neo-Synephrine)
  - Vasopressin (Pitressin)
  - Dobutamine (Dobutrex)
### Antihypertensive Agents

**Uncomplicated HTN**
- Stages 1 & 2 HTN = uncomplicated, non-emergency HTN
- First-line agents are thiazide diuretics and β-blockers because they are proven to reduce morbidity and mortality
- Alternative first-line agents include angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II-receptor blockers (ARBs), and calcium antagonists
- Vaso-dilators, α-blocking agents, α2 agonists and antiadrenergic agents are considered second-line antihypertensives

### Antihypertensive Agents

**HTN Crisis**
- Stage 3 HTN is considered a hypertensive crisis
- Represents either a hypertensive urgency (diastolic pressure of >120 mmHg without signs or symptoms of target organ complications) or a hypertensive emergency (elevated diastolic pressure accompanied by acute or chronic target organ injury)
- Treatment of HTN urgency and the reduction in blood pressure may span several hours or days
- HTN emergencies
  - can lead to intracranial hemorrhage, severe retinopathy, renal failure, unstable angina, acute left ventricular failure or dissecting aortic aneurysm
  - require invasive arterial blood pressure monitoring and immediate blood pressure reduction with parenteral hypertensives

### Antihypertensive Agents

**Angiotensin-Converting Enzyme Inhibitors (ACEI)**
- When there is a reduction in renal blood flow, rennin is released into the circulation, where it acts on angiotensinogen to produce angiotensin I
- In the pulmonary vasculature, angiotensin I is then converted by angiotensin-converting-enzyme (ACE) to angiotensin II, a very potent endogenous vasoconstrictor
- ACEIs block the conversion of angiotensin I to angiotensin II
- ACEIs are indicated for hypertension, heart failure and systolic dysfunction, secondary prevention of MI, left ventricular dysfunction and diabetic nephropathy

### Antihypertensive Agents

**Angiotension-Converting Enzyme Inhibitors (ACEI)**
- Nine ACEIs are available in the U.S.
  - Benazepril (Lotensin)
  - Fosinopril (Monopril)
  - Quinapril (Accupril)
  - Captopril (Capoten)
  - Lisinopril (Prinivil, Zestril)
  - Ramipril (Altace)
  - Enalapril (Vasotec)
  - Moexipril (Univasc)
  - Trandolapril (Mavik)
Antihypertensive Agents

• Angiotension II-Receptor Blockers (ARB)
  – Several non-renin and non-ACE pathways are used to produce angiotensin II
  – ACEIs do not completely block the synthesis of angiotensin II
  – ARBs are angiotension II type 1 (AT₁) receptor antagonists
    - AT₁ receptors are found in many tissues such as the vascular smooth muscle, myocardial tissue, brain, kidney, liver, uterus, and adrenal glands
    - The six ARBs available in the U.S. are:

<table>
<thead>
<tr>
<th>ARB</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Losartan</td>
<td>Cozaar</td>
</tr>
<tr>
<td>Irbesartan</td>
<td>Avapro</td>
</tr>
<tr>
<td>Valsartan</td>
<td>Diovan</td>
</tr>
<tr>
<td>Candesartan</td>
<td>Atacand</td>
</tr>
<tr>
<td>Telmisartan</td>
<td>Micardis</td>
</tr>
<tr>
<td>Eprosartan</td>
<td>Teveten</td>
</tr>
</tbody>
</table>

Antihypertensive Agents

• Calcium Channel Blockers
  – Vascular smooth muscle and cardiac cell contraction is dependent on the free intracellular calcium concentration
  – Calcium from the extracellular fluid enters either the high-voltage-gated L-type calcium channels or the low-voltage-gated T-type calcium channels
    - L-channel blockade mediates coronary and peripheral vasodilation and may also cause reflex sympathetic activation or a negative inotropic effect
    - T-channel blockade mediates coronary and peripheral vasodilation but does not cause reflex sympathetic activation
  – Conventional calcium channel blockers inhibit only L-channels

Antihypertensive Agents

• Calcium Channel Blockers
  – Verapamil and to a lesser extent diltiazem lower SA node automaticity and decrease AV node conduction and are indicated for the treatment of hypertension, angina and dysrhythmias

Antihypertensive Agents

• β Adrenergic Blocking Agents
  – The antihypertensive effects of β blockers are multimechanistic
    - Blockade of β receptors on the renal juxtaglomerular cells, leading to rennin blockade and decreased angiotensin II concentrations
    - Blockade of myocardial β receptors, leading to decreased cardiac contractility and heart rate, diminishing C.O.
    - Blockade of CNS β receptors, leading to decreased sympathetic output from the CNS and blockade of peripheral β receptors, decreasing norepinephrine concentrations
  – β blockers are indicated for essential hypertension, angina pectoris, cardiac dysrhythmias, 2° prevention of MI, CHF and pheochromocytoma
  – Possible β-blocker-induced pulmonary dysfunction includes bronchospasm, bronchial obstruction, rales, wheezing, dyspnea, cough and exacerbation of stable asthma or COPD
Antihypertensive Agents

• β Adrenergic Blocking Agents
  – Drugs in this class include
    – Acebutolol (Sectral)
    – Atenolol (Tenormin)
    – Betaxolol (Kerlone)
    – Labetalol (Normodyne)
    – Metoprolol (Lopressor)
    – Nadolol (Visken)
    – Propranolol (Inderal)

Antithrombotic Agents

• Three categories of antithrombotic agents are available
  – Anticoagulant
    • Prevent the formation of the fibrin clot and prevent further clot formation in already existing thrombi. Agents in this category include:
      • Indicated for the prophylaxis and treatment of
        – venous thromboembolism and pulmonary embolism
        – treatment of atrial fibrillation with embolization
        – diagnosis and treatment of disseminated intravascular coagulation
        – prophylaxis and treatment of peripheral arterial embolism
  – Antiplatelet
    • Inhibit the action of platelets in the clotting process
  – Thrombolytic
    • Indicated for the management of ST-segment-elevation acute MI
    • Reduce the incidence of heart failure and death associated with an acute MI
    • Restore coronary blood flow by dissolving the thrombus, thus limiting the extent of ischemia and necrosis
    • Patients should receive thrombolytic therapy within 12 hours of symptom onset
    • Most common side effects
      – minor bleeding (superficial and surface bleeding)
      – major bleeding (gastrointestinal, genitourinary, respiratory tract, retroperitoneal and intracranial hemorrhage)
Antithrombotic Agents

• Three categories of antithrombotic agents are available
  – Thrombolytic
    • Drugs in this class include
      – Alteplase (Activase)
      – Reteplase (Retavase)
      – Urokinase (Abbokinase)
      – Streptokinase (Streptase)
      – Anistreplase (Eminase)
      – Tenecteplase (TNKase)